PERRONE, GIULIA
PERRONE, GIULIA
DIPARTIMENTO DI EMATOLOGIA E SCIENZE ONCOLOGICHE "L. e A. SERAGNOLI"
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
2007 Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M.
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation.
2004 ARPINATI M; CHIRUMBOLO G; URBINI B; BONIFAZI F; BANDINI G; SAUNTHARARAJAH Y; ZAGNOLI A; STANZANI M; FALCIONI S; PERRONE G; TURA S; BACCARANI M.; RONDELLI D.
Ascorbic acid inhibits antitumor activity of bortezomib in vivo
2009 Perrone G; Hideshima T; Ikeda H; Okawa Y; Calabrese E; Gorgun G; Santo L; Cirstea D; Raje N; Chauhan D; Baccarani M; Cavo M; Anderson KC.
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes
2014 Lucia Pantani;Elena Zamagni;Beatrice Anna Zannetti;Annalisa Pezzi;Paola Tacchetti;Annamaria Brioli;Katia Mancuso;Giulia Perrone;Serena Rocchi;Patrizia Tosi;Michele Cavo
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma.
2012 Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perrone G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A.
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS
2010 Terragna C.; Remondini D.; Martinelli G.; Tosi P.; Zamagni E.; Tacchetti P.; Perrone G.; Brioli A.; Ceccolini M.; Testoni N.; Marzocchi G.; Castellani G.; Durante S.; Di Raimondo F.; Patriarca F.; Catalano L.; Masini L.; Ledda A.; Angelucci E.; Galieni P.; Gozzetti A.; Baccarani M.; Cavo M.
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation.
2006 Tosi P; Zamagni E; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Baccarani M; Cavo M.
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation.
2008 Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccolini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M.
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
2006 Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M.
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5
2012 Terragna, C; Martello, M; Martinelli, G; Durante, S; Pantani, L; Zamagni, E; Tacchetti, P; Brioli, A; Perrone, G; Zannetti, Ba; Borsi, E; Biasco, G; Baccarani, M; Cavo, M.
HIF 1 Alpha: A Suitable Target for Multiple Myeloma
2011 PERRONE G; BORSI E; TERRAGNA C; DURANTE S; MARTELLO M; ALUIGI M; MANCINI M; ZAMAGNI E; TACCHETTI P; BRIOLI A; PANTANI L; ZANNETTI BA; MARTINELLI G; SANTUCCI MA; BACCARANI M; CAVO M
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA
2012 G Perrone; E Borsi; C Terragna; M Martello; M Mancini; M Aluigi; MA Santucci; G Martinelli; M Baccarani; M Cavo
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment
2014 Enrica Borsi;Giulia Perrone;Carolina Terragna;Marina Martello;Elena Zamagni;Paola Tacchetti;Lucia Pantani;Annamaria Brioli;Angela Flores Dico;Beatrice Anna Zannetti;Serena Rocchi;Michele Cavo
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53
2012 Terragna C; Martello M; Pantani L; Patriarca F; Zamagni E; Galli M; Tacchetti P; Petrucci MT; Crippa C; Bringhen S; Brioli A; Offidani M; Perrone G; Zannetti BA; Borsi E; Testoni N; Marzocchi G; Baccarani M; Martinelli G; Cavo M.
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53
2011 TERRAGNA C; MARTELLO M; DURANTE S; PANTANI L; ZAMAGNI E; TACCHETTI P; BRIOLI A; PERRONE G; ZANNETTI BA; BORSI E; BACCARANI M; MARTINELLI G; CAVO M
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma.
2014 Borsi E;Perrone G;Terragna C;Martello M;Dico AF;Solaini G;Baracca A;Sgarbi G;Pasquinelli G;Valente S;Zamagni E;Tacchetti P;Martinelli G;Cavo M
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease.
2012 Brioli A;Zamagni E;Pasquali S;Tosi P;Tacchetti P;Perrone G;Pantani L;Petrucci A;Zannetti BA;Baccarani M;Cavo M
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma.
2012 Zamagni E; Petrucci A; Tosi P; Tacchetti P; Perrone G; Brioli A; Pantani L; Zannetti B; Terragna C; Baccarani M; Cavo M.
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone.
2006 Tosi P; Zamagni E; Cangini D; Tacchetti P; Di Raimondo F; Catalano L; D'ArcoA; Ronconi S; Cellini C; Offidani M; Perrone G; Ceccolini M; Brioli A; Tura S;Baccarani M; Cavo M.
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.
2006 Cavo M; Terragna C; Renzulli M; Zamagni E; Tosi P; Testoni N; Nicci C; Cangini D; Tacchetti P; Grafone T; Cellini C; Ceccolini M; Perrone G; Martinelli G; Baccarani M; Guardigni L.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. | Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini... D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. | ARPINATI M; CHIRUMBOLO G; URBINI B; BONIFAZI F; BANDINI G; SAUNTHARARAJAH Y; ZAGNOLI A; STANZANI ...M; FALCIONI S; PERRONE G; TURA S; BACCARANI M.; RONDELLI D. | 2004-01-01 | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Ascorbic acid inhibits antitumor activity of bortezomib in vivo | Perrone G; Hideshima T; Ikeda H; Okawa Y; Calabrese E; Gorgun G; Santo L; Cirstea D; Raje N; Chau...han D; Baccarani M; Cavo M; Anderson KC. | 2009-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes | Lucia Pantani;Elena Zamagni;Beatrice Anna Zannetti;Annalisa Pezzi;Paola Tacchetti;Annamaria Briol...i;Katia Mancuso;Giulia Perrone;Serena Rocchi;Patrizia Tosi;Michele Cavo | 2014-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. | Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perr...one G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A. | 2012-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS | Terragna C.; Remondini D.; Martinelli G.; Tosi P.; Zamagni E.; Tacchetti P.; Perrone G.; Brioli A....; Ceccolini M.; Testoni N.; Marzocchi G.; Castellani G.; Durante S.; Di Raimondo F.; Patriarca F.; Catalano L.; Masini L.; Ledda A.; Angelucci E.; Galieni P.; Gozzetti A.; Baccarani M.; Cavo M. | 2010-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. | Tosi P; Zamagni E; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Baccarani M; Cavo M. | 2006-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. | Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccol...ini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M. | 2008-01-01 | EUROPEAN JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. | Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; ...Tura S; Baccarani M; Cavo M. | 2006-01-01 | EUROPEAN JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 | Terragna, C; Martello, M; Martinelli, G; Durante, S; Pantani, L; Zamagni, E; Tacchetti, P; Brioli..., A; Perrone, G; Zannetti, Ba; Borsi, E; Biasco, G; Baccarani, M; Cavo, M. | 2012-01-01 | CANCER RESEARCH | - | 4.02 Riassunto (Abstract) | - |
| HIF 1 Alpha: A Suitable Target for Multiple Myeloma | PERRONE G; BORSI E; TERRAGNA C; DURANTE S; MARTELLO M; ALUIGI M; MANCINI M; ZAMAGNI E; TACCHETTI ...P; BRIOLI A; PANTANI L; ZANNETTI BA; MARTINELLI G; SANTUCCI MA; BACCARANI M; CAVO M | 2011-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA | G Perrone; E Borsi; C Terragna; M Martello; M Mancini; M Aluigi; MA Santucci; G Martinelli; M Bac...carani; M Cavo | 2012-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment | Enrica Borsi;Giulia Perrone;Carolina Terragna;Marina Martello;Elena Zamagni;Paola Tacchetti;Lucia... Pantani;Annamaria Brioli;Angela Flores Dico;Beatrice Anna Zannetti;Serena Rocchi;Michele Cavo | 2014-01-01 | EXPERIMENTAL CELL RESEARCH | - | 1.01 Articolo in rivista | - |
| High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 | Terragna C; Martello M; Pantani L; Patriarca F; Zamagni E; Galli M; Tacchetti P; Petrucci MT; Cri...ppa C; Bringhen S; Brioli A; Offidani M; Perrone G; Zannetti BA; Borsi E; Testoni N; Marzocchi G; Baccarani M; Martinelli G; Cavo M. | 2012-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 | TERRAGNA C; MARTELLO M; DURANTE S; PANTANI L; ZAMAGNI E; TACCHETTI P; BRIOLI A; PERRONE G; ZANNET...TI BA; BORSI E; BACCARANI M; MARTINELLI G; CAVO M | 2011-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. | Borsi E;Perrone G;Terragna C;Martello M;Dico AF;Solaini G;Baracca A;Sgarbi G;Pasquinelli G;Valent...e S;Zamagni E;Tacchetti P;Martinelli G;Cavo M | 2014-01-01 | ONCOTARGET | - | 1.01 Articolo in rivista | - |
| Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. | Brioli A;Zamagni E;Pasquali S;Tosi P;Tacchetti P;Perrone G;Pantani L;Petrucci A;Zannetti BA;Bacca...rani M;Cavo M | 2012-01-01 | BONE MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. | Zamagni E; Petrucci A; Tosi P; Tacchetti P; Perrone G; Brioli A; Pantani L; Zannetti B; Terragna ...C; Baccarani M; Cavo M. | 2012-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. | Tosi P; Zamagni E; Cangini D; Tacchetti P; Di Raimondo F; Catalano L; D'ArcoA; Ronconi S; Cellini... C; Offidani M; Perrone G; Ceccolini M; Brioli A; Tura S;Baccarani M; Cavo M. | 2006-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. | Cavo M; Terragna C; Renzulli M; Zamagni E; Tosi P; Testoni N; Nicci C; Cangini D; Tacchetti P; Gr...afone T; Cellini C; Ceccolini M; Perrone G; Martinelli G; Baccarani M; Guardigni L. | 2006-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |